Systemic delivery of siRNA by aminated poly(α)glutamate for the treatment of solid tumors
- 1 July 2017
- journal article
- Published by Elsevier in Journal of Controlled Release
- Vol. 257, 132-143
Abstract
No abstract availableKeywords
Funding Information
- European Research Council (617445)
- Israel Science Foundation (918/14)
This publication has 51 references indexed in Scilit:
- Polo-like kinase 1 as target for cancer therapyExperimental Hematology & Oncology, 2012
- The Effect of Chemical Modification and Nanoparticle Formulation on Stability and Biodistribution of siRNA in MiceMolecular Therapy, 2009
- Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in miceJournal of Clinical Investigation, 2009
- The balance of Polo-like kinase 1 in tumorigenesisCell Division, 2009
- Factors Affecting the Clearance and Biodistribution of Polymeric NanoparticlesMolecular Pharmaceutics, 2008
- Preclinical Studies To Understand Nanoparticle Interaction with the Immune System and Its Potential Effects on Nanoparticle BiodistributionMolecular Pharmaceutics, 2008
- The therapeutic potential of RNA interferenceFEBS Letters, 2005
- Potent and persistent in vivo anti-HBV activity of chemically modified siRNAsNature Biotechnology, 2005
- Induction of Inflammatory Cytokines and Interferon Responses by Double-stranded and Single-stranded siRNAs is Sequence-dependent and Requires Endosomal LocalizationJournal of Molecular Biology, 2005
- Plasma Heparin Levels in Normal ManCirculation, 1961